Hashash et al, 2008 |
Lebanon |
Rome III |
25 (56.0) |
2 |
F + M, 13(1 mg/day + 20 mg/day) Placebo, 12 |
antipsychotics and TCADs |
Patient-reported subjective feeling of global symptom relief |
Tack et al, 2009 |
Belgium, Germany and The Netherlands |
Rome II |
53 (66.0) |
4 |
R137696, 29(6 mg/day) Placebo, 24 |
5-HT1A receptor agonists |
30% improvement in patient assessment of upper gastrointestinal symptom severity |
Miwa et al, 2009 |
Japan |
Rome II |
150 (73.3) |
4 |
Tandospirone, 75(30 mg/day) Placebo, 75 |
5-HT1A receptor agonists |
Patient-reported total abdominal symptom score of 0 or 1 on a modified gastrointestinal symptom rating scale |
Braak et al, 2011 |
The Netherlands |
Rome II |
38 (60.5) |
8 |
Amitriptyline, 18(25 mg/day) Placebo, 20 |
TCADs |
30% improvement in patient assessment of upper gastrointestinal symptom severity |
Wu et al, 2011 |
Hong Kong, China |
Rome II |
107 (80.4) |
12 |
Imipramine, 55(50 mg/day) Placebo, 52 |
TCADs |
Patient-reported relief of global symptoms |
Tack et al, 2012 |
Belgium |
Rome II |
17 (76.5) |
4 |
Buspirone, 7(30 mg/day) Placebo, 10 |
5-HT1A receptor agonists |
30% improvement in patient-reported dyspepsia symptom severity |
Tan et al, 2012 |
Hong Kong, China |
Rome II |
193 (72.0) |
8 |
Sertraline, 98(50 mg/day) Placebo, 95 |
SSRIs, |
Patient-reported relief of global symptoms |
Tack et al, 2015 |
Belgium |
Rome III |
34 (85.3) |
8 |
Mirtazepine, 17(15 mg/day) Placebo, 17 |
tetracyclic antidepressants |
30% improvement in patient-reported dyspepsia symptom severity |
Talley et al, 2015 |
USA and Canada |
Rome II |
292 (75.0) |
12 |
Amitriptyline, 97(25-50 mg/day) escitalopram, 98(10 mg/day) Placebo, 97 |
TCADs SSRIs |
Patient-reported adequate relief of global symptoms for 50% of weeks during weeks 3–12 |
Kaosombatwattana U et al, 2018 |
Bangkok, Thailand |
Rome III |
61(70.0) |
8 |
Nortriptyline, 28(10 mg/day) Placebo, 33 |
TCADs |
50% improvement in patient-reported dyspepsia symptom score |